OKYO Pharma’s (LON: OKYO) shares jumped 20% in early Thursday trading, hitting 2.7p per share after the company announced its Investigational New Drug (IND) application has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase 2 clinical study of OK-101 for the treatment of dry eye disease (DED).
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Despite the rise, OKYO’s shares are down 61% in 2022.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“We are very pleased to receive clearance from the FDA to initiate our OK-101 Phase 2 study,” said Gary Jacob, Chief Executive Officer of OKYO Pharma. “We believe this first-in-human study will help demonstrate that OK-101 may provide a new way to treat DED patients who are not well-served by currently approved drugs.”
Top Broker Recommendation
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Following previous feedback from the FDA, the company said that they are designating primary and secondary efficacy endpoints in the Phase 2 study of OK-101, which includes a sign and a symptom of the disease.
In addition, the company believes that if its Phase 2 study meets its primary endpoint, it could accelerate the timeline to a new drug application (NDA) filing for OK-101.
“The clearance of our IND for OK-101 has been a key priority for the company this past year, and we are excited to be moving this drug into the clinic in the first quarter of 2023,” Jacob added.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
